BIOGEN INC. (BIIB) Free cash flow 2016–2025
BIOGEN INC. (BIIB) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$2.1BFY2025 · since FY2016: $4.0B → $2.1B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $2.1B | -24.7% |
| FY2024 | $2.7B | +114.3% |
| FY2023 | $1.3B | +11.0% |
| FY2022 | $1.1B | -66.2% |
| FY2021 | $3.4B | -11.1% |
| FY2020 | $3.8B | -42.0% |
| FY2019 | $6.6B | +21.2% |
| FY2018 | $5.4B | +47.1% |
| FY2017 | $3.7B | -7.2% |
| FY2016 | $4.0B | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More BIIB financial trends
BIIB RevenueBIIB Net incomeBIIB Net marginBIIB Gross profitBIIB Gross marginBIIB Operating incomeBIIB Operating marginBIIB Operating cash flowBIIB Capital expendituresBIIB Return on equityBIIB Stock buybacksBIIB Dividends paidBIIB Total assetsBIIB Total liabilitiesBIIB Shareholders’ equityBIIB overview →